Literature DB >> 2286588

Infection prophylaxis in neutropenic patients with acute leukaemia--a randomized, comparative study with ofloxacin, ciprofloxacin and co-trimoxazole/colistin.

M Arning1, H H Wolf, C Aul, A Heyll, R E Scharf, W Scheider.   

Abstract

Preliminary results are presented of an ongoing, prospective, randomized, study comparing ofloxacin, ciprofloxacin and co-trimoxazole/colistin for the prevention of infection in patients with acute leukaemia. The results for 59 patients (median age 47 years, range 21-72) included 88 episodes of neutropenia, each associated with a course of cytotoxic therapy. The main factor measured was the time elapsed from the beginning of neutropenia (neutrophils less than 500/microliter) until the first infectious febrile episode. The median time for the period was 12 days (range 1-56) for the cotrimoxazole/colistin group, 15 days (range 1-38) for the ofloxacin group and 20 days (range 1-36) for the ciprofloxacin group (differences not significant). Microbiologically proven major infections occurred in 10/27 treatment courses with co-trimoxazole/colistin 7/31 courses with ofloxacin and 7/30 courses with ciprofloxacin (P not significant). These were mostly due to Gram-positive cocci. There were no Gram-negative infections in the quinolone groups compared with one major Pseudomonas aeruginosa infection in the co-trimoxazole/colistin group. No Pneumocystis carinii infections were encountered. Adverse reactions associated with co-trimoxazole/colistin required discontinuation of medication in 11/27 treatment courses because of compliance problems, skin reactions or gastrointestinal intolerance. There were significantly fewer discontinuations in the ofloxacin (n = 2) and in the ciprofloxacin groups (n = 3). Major side effects of the quinolones included persistent icterus in one patient receiving ofloxacin and psychiatric symptoms in one patient receiving ciprofloxacin. It is concluded from these data that there were no statistically significant differences between the three treatment groups in respect of the prevention of infection.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2286588     DOI: 10.1093/jac/26.suppl_d.137

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

Review 1.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 2.  Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.

Authors:  Anat Stern; Hefziba Green; Mical Paul; Liat Vidal; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2014-10-01

3.  Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center.

Authors:  Michele Pohlen; Julia Marx; Alexander Mellmann; Karsten Becker; Rolf M Mesters; Jan-Henrik Mikesch; Christoph Schliemann; Georg Lenz; Carsten Müller-Tidow; Thomas Büchner; Utz Krug; Matthias Stelljes; Helge Karch; Georg Peters; Hans U Gerth; Dennis Görlich; Wolfgang E Berdel
Journal:  Haematologica       Date:  2016-07-28       Impact factor: 9.941

4.  Prophylactic antibiotics eliminate bacteremia and allow safe outpatient management following high-dose chemotherapy and autologous stem cell rescue.

Authors:  B Meisenberg; R Gollard; T Brehm; R McMillan; W Miller
Journal:  Support Care Cancer       Date:  1996-09       Impact factor: 3.603

Review 5.  Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.

Authors:  Anat Gafter-Gvili; Abigail Fraser; Mical Paul; Liat Vidal; Theresa A Lawrie; Marianne D van de Wetering; Leontien C M Kremer; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

6.  Comparison of antibiotic prophylaxis with cotrimoxazole/colistin (COT/COL) versus ciprofloxacin (CIP) in patients with acute myeloid leukemia.

Authors:  Karin Mayer; Corinna Hahn-Ast; Sara Mückter; Andrea Schmitz; Simon Krause; Linda Felder; Isabelle Bekeredjian-Ding; Ernst Molitor; Peter Brossart; Marie von Lilienfeld-Toal
Journal:  Support Care Cancer       Date:  2015-01-24       Impact factor: 3.603

Review 7.  Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts.

Authors:  G Maschmeyer
Journal:  Drugs       Date:  1993       Impact factor: 9.546

8.  Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.

Authors:  W V Kern; E Andriof; M Oethinger; P Kern; J Hacker; R Marre
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 9.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

10.  Concentration of pefloxacin in feces during infection prophylaxis in neutropenic patients.

Authors:  J J van de Leur; E J Vollaard; A J Janssen; A S Dofferhoff
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.